Fair Prescription Drug Competition Act

Summary

Fair Prescription Drug Competition Act - Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the 180-day exclusivity period granted to the generic manufacturer.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 16 February 2011

   Introduced

   Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

   Source: IntroReferral

2. 16 February 2011

   Introduced

   Sponsor introductory remarks on measure. (CR S797)

   Source: IntroReferral

3. 16 February 2011

   Introduced

   Introduced in Senate

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in Senate · 16 February 2011 · Official file

Documents

3 official files

• Introduced in Senate (text)

  Introduced in Senate · EN · 16 February 2011

  ViewDownloadOpen at official source

• Introduced in Senate (PDF)

  Introduced in Senate · EN · 16 February 2011

  ViewDownloadOpen at official source

• Introduced in Senate

  summary · EN · 16 February 2011

  Open at official source

Sponsors

• Sen. Rockefeller, John D., IV [D-WV] · D · Sponsor
• Jeanne Shaheen · D · Sponsor
• Sen. Leahy, Patrick J. [D-VT] · D · Sponsor
• Sen. Inouye, Daniel K. [D-HI] · D · Sponsor
• Sen. Stabenow, Debbie [D-MI] · D · Sponsor
• Charles Schumer · D · Sponsor
• · sshr00 · Standing

Related records

• related to → To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.